Two Grindeks subsidiaries receive Russian Good Manufacturing practice certificates

Two Grindeks subsidiaries receive Russian Good Manufacturing practice certificates


JSC Tallinn Pharmaceutical Plant (Estonia) and HBM Pharma (Slovakia) have received Russian Good Manufacturing practice (GMP) certificates.

Quality director of JSC Grindeks, Dr.chem. Juris Hmeļņickis points out that receiving GMP certificates is a positive development for the whole Grindeks Group and it will contribute to export to Russian market in 2017 and hereafter.

This certificate confirms high culture of the company’s manufacturing and shows that the company’s quality system is properly planned and implemented, as well as the certificate is a guarantee of quality medicines. European Union GMP certificates for both Grindeks subsidiaries were acquired a long time ago and that allowed export of products to many countries outside the EU, including Russia. The situation has changed since 2016 and foreign pharmaceutical manufacturers who wish to distribute their products in the Russian Federation are obliged to receive Russian GMP certificate, otherwise the registration of new preparations would be impossible. Also, since 1 January 2017, manufacturers who have not received this certificate cannot re-register drugs that are already on the market.

“Inspection representatives from Russia carried out inspections in JSC Tallinn Pharmaceutical Plant and HBM Pharma, spending three days in each of them and concluded that quality standards of products fully comply with Russian GMP standard requirements,” tells J.Hmeļņickis, “we can be proud of the fact that both our factories passed the inspection, because not all foreign medicine manufacturers managed to achieve such good results. It is clear that a decision on the compulsory introduction of such a certificate has been focused on the development of Russian domestic market, hence we perceive it as another obstacle, which we managed to successfully overcome without prejudice to export volumes.” GMP certificate is issued for three years and will be valid until 2019.

JSC Tallinn Pharmaceutical Plant is currently specializing in ointment manufacturing and is equipped with new facilities that allow increasing manufacturing capacity and quality of products. Within the product range of manufacturing plant there are unique ointments that are popular among patients and healthcare specialists – Viprosal B® and Capsicam®.

HBM Pharma was established in 1992 and its manufacturing processes comply with the EU requirements of GMP standards. Manufacturing capacity of HBM Pharma is 60 million ampoules and 400 million tablets per year.

Related posts


On Grindeks results in 2015

Today, on 26 February, the JSC Grindeks submitted the non-audited consolidated financial statements of 2015 to Nasdaq Riga. Non-audited financial results indicate that the Group’s turnover in 2015 was 82.9 million euros and has decreased by 5.6 million euros or 6.3% in comparison to 2014. In 2015, the Group’s net profit, attributable to shareholders of […]

JSC Grindeks celebrates Ridgepole celebrations of the new Purification plant building

On the 3rd of June Joint-stock company Grindeks celebrates Ridgepole celebrations of the new waste water purification plant building, thus expressing support to the World Environment Day whose theme this year is Green Cities. The Purification plant is being constructed, in order to prevent efficiently the possible harm to the environment. Construction of the purification plant […]
manufacturing expansion

On Grindeks manufacturing expansion

Referring to the information published in Latvian media, which states that JSC Grindeks plans to move its manufacturing outside Latvia, we explain that the company’s management is examining various options to increase the manufacturing capacity. This includes starting up manufacturing in other countries or manufacturing expansion in existing Grindeks Group’s manufacturing units. Decision has been […]